Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting.
- Published In:
- Annals of translational medicine, 10(3), 152 (2022)
- Authors:
- Hu, Ying, Zheng, Shui-Lian, Ye, Xiao-Lan, Shi, Jia-Na, Zheng, Xiao-Wei, Pan, Han-Sheng, Zhang, Yi-Wen, Yang, Xiu-Li, Huang, Ping
- Database ID:
- RPEP-06202
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06202APA
Hu, Ying; Zheng, Shui-Lian; Ye, Xiao-Lan; Shi, Jia-Na; Zheng, Xiao-Wei; Pan, Han-Sheng; Zhang, Yi-Wen; Yang, Xiu-Li; Huang, Ping. (2022). Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting.. Annals of translational medicine, 10(3), 152. https://doi.org/10.21037/atm-22-200
MLA
Hu, Ying, et al. "Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting.." Annals of translational medicine, 2022. https://doi.org/10.21037/atm-22-200
RethinkPeptides
RethinkPeptides Research Database. "Cost-effectiveness analysis of 4 GLP-1RAs in the treatment o..." RPEP-06202. Retrieved from https://rethinkpeptides.com/research/hu-2022-costeffectiveness-analysis-of-4
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.